Mesoblast Ltd
Company Profile
Business description
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Contact
55 Collins Street
Level 38
MelbourneVIC3000
AUST: +61 396396036
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
73
Stocks News & Analysis
stocks
Shorts circle BHP ahead of listing unification: ASX’s most shorted stocks
stocks
Mayne Pharma woes to persist for 2020
stocks
CSL remains favourite, but biotech field broadening
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,833.60 | 4.90 | 0.06% |
CAC 40 | 7,754.55 | 16.13 | 0.21% |
DAX 40 | 23,934.13 | 144.02 | 0.61% |
Dow JONES (US) | 44,828.53 | 344.11 | 0.77% |
FTSE 100 | 8,823.20 | 48.51 | 0.55% |
HKSE | 24,069.94 | 151.47 | -0.63% |
NASDAQ | 20,601.10 | 207.97 | 1.02% |
Nikkei 225 | 39,785.90 | 23.42 | 0.06% |
NZX 50 Index | 12,704.48 | 79.81 | -0.62% |
S&P 500 | 6,279.35 | 51.93 | 0.83% |
S&P/ASX 200 | 8,595.80 | 1.90 | -0.02% |
SSE Composite Index | 3,461.15 | 6.36 | 0.18% |